GlassScriptPhysician profile
Obaid Ashraf
NPI 1982056586
$11,741.99
in general payments reported to CMS, 2019-2025
20 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 78% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $125 · 2021: $309 · 2022: $3,474 · 2023: $4,675 · 2024: $1,746 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $2,611 · Travel and Lodging: $1,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $2,611.16 |
| Travel and Lodging | $1,893.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,636.33 | 2022-2024 | Da Vinci Surgical System |
| Insmed, INC. | $901.79 | 2019-2025 | Arikayce, Brinsupri |
| Pinnacle Biologics, INC | $899.88 | 2024 | Photofrin |
| Astrazeneca Pharmaceuticals LP | $453.22 | 2020-2025 | Fasenra |
| Inari Medical, INC. | $303.82 | 2021-2022 | |
| Glaxosmithkline, LLC. | $266.91 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.86 | 2019-2025 | Ofev |
| Pulmonx Corporation | $230.46 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Caris Mpi, INC. | $174.00 | 2025 | Mi Cancer Seek |
| Mylan Specialty L.P. | $149.70 | 2023 | Yupelri |
| Haemonetics Corporation | $111.30 | 2024 | Teg6s Hemostasis System |
| Novartis Pharmaceuticals Corporation | $110.48 | 2023 | |
| Abbott Laboratories | $72.48 | 2024 | Freestyle Libre |
| Abiomed | $47.59 | 2025 | |
| Amgen INC. | $39.94 | 2025 | Tezspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $33.21 | 2024 | Acthar |
| Viatris Specialty LLC | $25.87 | 2025 | Yupelri |
| Pfizer INC. | $17.73 | 2024 | |
| Merck Sharp & Dohme LLC | $17.15 | 2024 | |
| Inspire Medical Systems, INC. | $14.27 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obaid Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.